CERENO SCIENTIFIC Aktie

 

GOTHENBURG, Sweden, Dec. 12, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will attend JPM Week 2026......

GOTHENBURG, Sweden, Dec. 8, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration......

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will present new data of CS014 at the scientific conference Pharmacology 2025 organized by the British Pharmacology Society on December 16-18 in Belfast, Northern Ireland. The findings relate to CS014's preclinical studies and Phase I trial, supporting advancement of the program into Phase II development. CS014 is being developed as a next-generation HDAC inhibitor and novel chemical...

Cereno Scientific (Nasdaq First North: CRNO B) (the “Company”), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, announced that major long-term shareholders and new investors have confirmed their strong support by participating in the recently communicated financing arrangement, amounting to a total of up to SEK 665 million with SEK 100 million raised in a directed share issue (the “Directed Issue”), warrants with premium strike prices that may add further equity capital of up to 200 million, and up to SEK 350...

Correction: In the press release published on November 28, 2025, the total financing amount was incorrectly stated as up to SEK 650 million upon full exercise of warrants and convertibles. The correct total amount is up to SEK 665 million. The full corrected press release is provided below. No other information has been changed. THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER...

Cereno Scientific (Nasdaq First North: CRNO B) (the “Company”), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, announced that major long-term shareholders and new investors have confirmed their strong support by participating in the recently communicated financing arrangement, amounting to a total of up to SEK 650 million with SEK 100 million raised in a directed share issue (the “Directed Issue”), warrants with premium strike prices that may add further equity capital of up to 200 million, and up to SEK 350...

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE. Cereno Scientific (Nasdaq First North: CRNO B) (the “Company”), an innovative biotech pioneering treatments to enhance and extend...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the Board of Directors and Chief Executive Officer of Cereno Scientific AB here presents the Interim Report for Q3 2025 (July 1 – September 30, 2025). Financial overview Cereno Scientific Group – Q3 · Net Sales were SEK 0 (0) · Result after financial items was SEK -21 321 915 (-22 718 087) · Earnings per share was SEK -0.07 (-0.08) before dilution and SEK -0.07 (-0.07) after...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the Board of Directors and Chief Executive Officer of Cereno Scientific AB here presents the Interim Report for Q3 2025 (July 1 – September 30, 2025). Financial overview Cereno Scientific Group – Q3 · Net Sales were SEK 0 (0) · Result after financial items was SEK -21 321 915 (-22 718 087) · Earnings per share was SEK -0.07 (-0.08) before dilution and SEK -0.07 (-0.07) after...

Cereno Scientific (Nasdaq First North: CRNO B) (“the Company”), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, announces today that Arena Investors, LP (“Arena”) has requested exercise of 600,000 warrants of series 2024/2029, which were issued to Arena in connection with the financing agreement (the “Financing Agreement”) being entered into on November 11, 2024. The new Class B shares have been registered the Swedish Companies Registration Office (Bolagsverket). Cereno Scientific receives approximately SEK 4...

GOTHENBURG, Sweden, Nov. 10, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the submission of the clinical trial......

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will participate at the global partnering event BIO-Europe Fall in Vienna, Austria, on November 3–5, 2025. Recognized as Europe's premier biopharma partnering event, BIO-Europe Fall provides a unique platform for forging collaborations that drive innovation and accelerate the development of new treatments. “BIO-Europe Fall is a cornerstone for advancing collaborations in the life...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will participate at the Nordic Life Science Days (NLSDays) on October 13-14, 2025, in Gothenburg, Sweden. This is the premier Nordic life science event attended by decision-makers from bio- and medtech, pharma, finance, and research. “Nordic Life Science Days is an important platform for engaging with potential partners and investors, and we are pleased to highlight Cereno Scientific'...

Cereno Scientific (Nasdaq First North: CRNO B) (“the Company”), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that Fenja Capital II A/S and Arena Investors, LP (the “Financiers”) have called for the conversion of all remaining convertibles totaling SEK 25 million into new Class B shares in the Company, in accordance with the financing agreement (the “Financing Agreement”) entered into on 11 November 2024. The new Class B shares have today been registered with the Swedish Companies Registration...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that its CEO Sten R. Sörensen is a finalist for 'CEO of the Year' at the European Lifestars Awards 2025. The Awards celebrate the achievements from remarkable breakthroughs to transformational investments and deals of the exceptional individuals, teams, and organizations that have shaped the life science industry over the past 12 months. The 'CEO of the Year' category recognizes leaders who have...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will present at GoCo Investor Day hosted by GoCO Health Innovation City and AstraZeneca BioVentureHub. The event is held on Tuesday September 9, 2025. Cereno Scientific will present the company at 10:45. A recording of the presentation will be available on our web page after the event. The event is held between 08:30-14:45 at GoCo House, Entreprenörsstråket 10, Mölndal. More...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the Board of Directors and Chief Executive Officer of Cereno Scientific AB here presents the Interim Report for Q2 2025 (April 1 – June 30, 2025). Financial overview Cereno Scientific Group – Q2 · Net Sales were SEK 0 (0) · Result after financial items was SEK -26 626 999 (-21 234 039) · Earnings per share was SEK -0.09 (-0.08) before dilution and SEK -0.08 (-0.91) after dilution...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program, CS1, for the treatment of pulmonary arterial hypertension (PAH). Fast Track designation is designed to accelerate the development and regulatory review of new therapies for serious conditions with high unmet medical need. The designation highlights CS1's potential as a differentiated treatment...

Cereno Scientific (Nasdaq First North: CRNO B) (“the Company”), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that Fenja Capital II A/S and Arena Investors, LP (the “Financiers”) have called for the conversion of convertibles totaling SEK 25 million into new Class B shares in the Company, in accordance with the financing agreement (the “Financing Agreement”) entered into on 11 November 2024. The new Class B shares have today been registered with the Swedish Companies Registration Office (...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced positive topline results from its Phase I trial of CS014, a novel HDAC inhibitor in development for idiopathic pulmonary fibrosis (IPF). The trial confirms a favorable safety and tolerability profile, and data support further clinical evaluation. Based on the findings, preparations are underway to initiate a Phase II trial. “We are very pleased with the outcome of this study and the excellent...